CNS Programs

About Fosun Pharma

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive pharmaceutical and healthcare conglomerate that has evolved from a Chinese pharmaceutical company into a global innovation leader. The company operates through diversified business segments including pharmaceutical manufacturing, vaccines, medical devices, medical diagnostics, and healthcare services, while also maintaining significant positions in pharmaceutical distribution through its Sinopharm investment. Fosun Pharma has established technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy, with particular focus on first-in-class and best-in-class drug development. The company's commitment to innovation is demonstrated through its substantial R&D expenditure of RMB 5.554 billion in FY2024 and its successful development of globally recognized products like Artesun®, which has treated over 56 million severe malaria patients worldwide.

About Unity Biotechnology

Unity Biotechnology is pioneering a novel approach to treating age-related diseases by targeting senescent cells, which accumulate with age and contribute to tissue dysfunction and chronic inflammation. The company's core technology focuses on inhibiting Bcl-xL, a pro-survival protein in senescent cells, to induce their apoptosis. Its most advanced candidate, UBX1325, has shown promising results in mid-stage trials for retinal diseases, positioning Unity at the forefront of the emerging senolytic therapeutics field. The company is publicly traded and continues to advance its pipeline while exploring new indications for its platform.

Therapeutic Areas

Other Neurological Disorders Drugs